Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth

Summary

Viva Biotech announced its 2026 interim results with revenue reaching RMB1,006.5 million, a 21.0% year-over-year increase, while gross profit grew 0.7% YoY to RMB341.7 million. The company highlighted AI integration in drug R&D and acceleration in CDMO commercial manufacturing as key growth drivers.